These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37543540)

  • 1. Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study.
    Faravelli I; Gagliardi D; Abati E; Meneri M; Ongaro J; Magri F; Parente V; Petrozzi L; Ricci G; Farè F; Garrone G; Fontana M; Caruso D; Siciliano G; Comi GP; Govoni A; Corti S; Ottoboni L
    Cell Mol Life Sci; 2023 Aug; 80(8):241. PubMed ID: 37543540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
    Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
    Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
    Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
    Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy.
    Schafernak KT; Jacobsen JR; Hernandez D; Kaye RD; Perez SE
    Acta Cytol; 2022; 66(1):79-84. PubMed ID: 34515035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy.
    Errico F; Marino C; Grimaldi M; Nuzzo T; Bassareo V; Valsecchi V; Panicucci C; Di Schiavi E; Mazza T; Bruno C; D'Amico A; Carta M; D'Ursi AM; Bertini E; Pellizzoni L; Usiello A
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
    Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
    Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
    Aslesh T; Yokota T
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.